1,721,341 research outputs found
Effects of Vinorelbine on quality of life and survival of elderly patients with advanced Non-Small-Cell Lung Cancer
No full textLong term efficacy and safety of latanoprost in glaucoma patients inadequately controlled on timolol
No full textEndogenous growth hormone secretion does not correlate with growth in patients with Turner's syndrome
No full textAmoxicillin/clavulanate versus cefaclor for treatemnt of acute otitis media in children with a history of recurrent AOM
No full text
Azithromycin-resistant Neisseria gonorrhoeae strains recently isolated in Italy
No full textAzithromycin-resistant Neisseria gonorrhoeae strains recently
isolated in Ital
Felbamate in therapy-resistant epilepsy: an Italian experience.
No full textWe evaluated the use of felbamate in 379 adults and children with refractory epilepsies in an open-label, compassionate clinical use setting. Prior to the termination of the program, because of reports of aplastic anemia, 351 patients had completed 2 months of treatment with felbamate at a dose of 2400-3600 mg/day for adults or 30-45 mg/kg/day for children. Of the 246 patients who had a diagnosis of therapy-refractory localization-related epilepsy with or without secondary generalization, 52% (126/246) achieved a seizure reduction of 50% or more, including 10% (25/246) who became seizure free. There was no difference in response rate between adults and children. Of the 80 patients who had a diagnosis of Lennox-Gastaut syndrome (LGS), 60% (48/80) achieved a seizure reduction of 50% or more, including 6% (5/80) who became seizure free. Of the 25 patients with a diagnosis of generalized epilepsy (other than LGS) or undetermined epilepsy whether focal or generalized, 60% (15/25) achieved a seizure reduction of 50% or more, including 12% (3/24) who became seizure free. The results of this uncontrolled study suggest that felbamate could be useful in patients with
epilepsies which are refractory to other antiepileptic drugs after careful risk-benefit assessment and consideration of all circumstances involve
Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell-lung cancer
No full textVinorelbine, a semisynthetic
vinca alkaloid, represents a welltolerated treatment for elderly patients with advanced non-small-cell lung cancer (NSCLC). We explored the quality of life (QoL) of such patients in a multicenter
randomized trial that compared
vinorelbine treatment with supportive care alone. Methods: Eligible patients were 70 years of age or older,
had stage IV or IIIB NSCLC that was ineligible for radiotherapy, and had a
performance status of 0–2 (a status of fully active to a status of capable of all
self-care but unable to work). Vinorelbine was given intravenously on days 1 and 8 of a 21-day treatment cycle, for a total of six cycles. QoL was evaluated with European Organization for Research and Treatment of Cancer questionnaires QLQ-C30 and QLQ-LC13, and the QoL data were analyzed by fitting
a linear mixed model for each QoL scale. Survival curves were plotted and were compared with the Mantel–
Haenszel test. Relative hazards of death and 95% confidence intervals (CIs)
were estimated by the Cox model.
Results: Investigators, blinded to the results,
stopped the trial early because of a low enrollment rate. (From April 1996 to November 1997, 191 of the 350
targeted patients were randomly assigned.) Data from 161 patients have been analyzed. Vinorelbine-treated patients scored better than control patients on QoL functioning scales, and
they reported fewer lung cancerrelated symptoms but reported worse toxicity-related symptoms. There was a
statistically significant (two-sided P = .03) survival advantage for patients receiving vinorelbine; median survival increased from 21 to 28 weeks in the vinorelbine-treated group. The relative
hazard of death for vinorelbine-treated
patients was 0.65 (95% CI = 0.45–0.93).
Conclusion: Vinorelbine improves survival of elderly patients with advanced NSCLC and possibly improves overall
QoL
Minimally invasive radio-guided parathyroidectomy on a group of 452 primary hyperparathyroid patients: refinement of preoperative imaging and intraoperative procedure
No full textHand-arm vibration and dose-response relation for vibration induced white finger among quarry drillers and stone carvers
No full text- …
